Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Florida Gets 36% Raise From Pfizer Under New Disease Management Contract

Executive Summary

Pfizer's contract extension with Florida provides a 36% increase in savings from disease management programs over the previous agreement

You may also be interested in...



Medicare Rx Winners May Be Determined By Formulary, Policy-Savvy

Formulary coverage will be crucial for pharmaceutical companies to realize the rewards of the Medicare drug benefit, a former Senate staffer says

Pfizer And Lockheed Martin Will Test Disease Management Program

Pfizer expects to have results from a study of its "Know Your Health" disease management program in Lockheed Martin employees by March 2005

Neurontin Off-Label Use Needs Prior Authorization Under Fla. Medicaid Plan

Prior authorization for off-label use of Pfizer's Neurontin would save the Florida Medicaid program $7 mil., the FY 2004-2005 budget proposal states

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel